Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE tezepelumab oral corticosteroid reduction study in adults with oral corticosteroid-dependent asthma
2023-504648-33-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezspire with Placebo (2 arms). Primary endpoint: Categorized percent reduction from baseline in daily maintenance oral corticosteroid dose at Week 28 while maintaining asthma control. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-504648-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504648-33-00.